Amdipharm acquisition - Comments from Economist Intelligence Unit
Amdipharm is one of the companies that has supposedly found ways to make money out of patent expiry, snapping up drugs that have come off-patent and that research-based pharma companies now see as too low-margin to be worth marketing. In 2011 its UK arm was still loss-making, according to registry filings recorded by Orbis, although its Irish and International arms have been more successful.
“Given rising demand for generic products, and the new pro-generic legislation that has been introduced in many countries over the past few years, there should be opportunities for growth. Moreover, there is plenty of potential to buy up new products, given the market has now reached the peak years for patent expiry. According to government figures, 28 medicines currently marketed in the UK are set to lose their patents by the end of this year (or £1bn-worth, according to Teva UK), with a further 21 coming off patent in 2013
